Drug Profile
Lomitapide - Amryt Pharma/University of Pennsylvania
Alternative Names: AEGR-733; BMS-201038; JUXTAPID; Juxtapid; LojuxtaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Developer Amryt Pharma; University of Pennsylvania
- Class Antihyperlipidaemics; Benzamides; Biphenyl compounds; Fluorenes; Piperidines; Small molecules
- Mechanism of Action Microsomal triglyceride transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Hyperlipoproteinaemia type IIa
- Phase III Hyperlipoproteinaemia type I